Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06378047 · ClinicalTrials.gov registry record · Phase 1
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT06378047 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT06378047, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).
Interventions
- DRUG Pembrolizumab
- DEVICE Irreversible Electroporation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2025-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06378047
The ClinicalTrials.gov registry entry for NCT06378047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06378047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06378047 about?
NCT06378047 is a clinical study titled "Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer". This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic re...
What is the current status of trial NCT06378047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2024-04-10. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT06378047?
The interventions under investigation include: Pembrolizumab (DRUG), Irreversible Electroporation (DEVICE).
Who is sponsoring clinical trial NCT06378047?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.